|
|
|
| Clinical effect of Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy in the treatment of brain metastasis of non-small cell lung cancer |
| LI Wenge GE Wei |
| Department of Oncology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
Abstract Objective To investigate the short-term efficacy and safety of Icotinib Hydrochloride Tablets (Conmana) combined with whole-brain radiotherapy in the treatment of advanced non-small cell lung cancer with brain metastasis. Methods The clinical data of 142 patients with non-small cell lung cancer with brain metastasis admitted to the Renmin Hospital of Wuhan University from February 2013 to February 2016 were retrospectively analyzed. According to the treatment approaches, they were divided into 51 cases in the group of Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy, 51 cases in the group of Icotinib Hydrochloride Tablets and 40 cases in the group of whole-brain radiotherapy. In the Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy group, whole-brain radiotherapy was performed simultaneously with oral administration of Icotinib Hydrochloride Tablets. The radiotherapy dose was 40-50 Gy/20-25 F, and the radiotherapy was completed within one month. Icotinib Hydrochloride Tablets were taken orally once a day at the beginning of radiotherapy, and the dose was 125 mg, 3 times a day. In the Icotinib Hydrochloride Tablets group, one Icotinib Hydrochloride Tablet was taken orally every day at a dose of 125 mg, 3 times a day. The whole-brain radiotherapy group received a radiotherapy dose of 40-50 Gy/20-25 F. The radiotherapy was completed within one month. In the three groups, the drug of parients was discontinued until the disease progressed or an intolerable toxic reaction occurred, and the progression-free survival time was calculated from the start of treatment until the disease progressed. Chi-square test was used to analyze whether there were significant differences in objective response rate, disease control rate and incidence of adverse reactions among the three groups of patients, and Kaplan-Meier test was used to analyze whether there were significant differences in progression-free survival among the three groups of patients. Results The objective response rate and disease control rate of Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy group were higher than those of the Icotinib Hydrochloride Tablets group and the whole-brain radiotherapy group, the differences were statistically significant (all P ＜ 0.05). There was no significant difference in the objective response rate and disease control rate between the Icotinib Hydrochloride Tablets group and the whole-brain radiotherapy group (P ＞ 0.05). Median progression-free survival in the Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy group was higher than that in the Icotinib Hydrochloride Tablets group and higher than that in the whole-brain radiotherapy group, the differences were statistically significant (all P ＜ 0.05). The median progression-free survival time of the Icotinib Hydrochloride Tablets group was not significantly different from that of the whole-brain radiotherapy group (P ＞ 0.05). The one-year survival rate of Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy group was 66.7% higher than that of the Icotinib Hydrochloride Tablets group (41.2%) and the whole-brain radiotherapy group (37.5%), with statistically significant differences (all P ＜ 0.05). There was no significant difference in the incidence of adverse reactions among the three groups of parients (P ＞ 0.05). Conclusion Icotinib Hydrochloride Tablets combined with whole-brain radiotherapy can significantly improve the disease control rate and progression-free survival time of patients with tolerable adverse reactions.
|
|
|
|
|
|
[1] Miller KD，Nogueira L，Mariotto AB，et al. Cancer treatment and survivorship statistics，2019 [J]. CA，2019，69（1）：7-34.
[2] Dempke WC，Edvardsen K，Lu S，et al. Brain Metastases in NSCLC are TKIs Changing the Treatment Strategy?[J]. Anticancer Res，2015，35（11）：5797-5806.
[3] 丁婕，戴旭，孟宪运，等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复，2015，22（9）：1150-1152.
[4] 抗癌药急性及亚急性毒性反应分度标准（WHO标准）[J].癌症，1992，4（3）：254.
[5] Pedrosa RMSM，Mustafa DAM，Aerts JGJV，et al. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis [J]. Front Oncol，2018，8：159.
[6] Sperduto PW，Yang TJ，Beal K，et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases：An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers（Lung-molGPA）[J]. JAMA Oncol，2017，3（6）：827-831.
[7] Yang JC，Wu YL，Schuler M，et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma（LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised，phase 3 trials [J]. Lancet Oncol，2015，16（2）：141-151.
[8] Tan J，Li M，Zhong W，et al. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC：A direct comparative analysis of icotinib，gefitinib，and erlotinib in a nude mouse model [J]. Oncotarget，2017，8（58）：98771-98781.
[9] Jackman DM，Cioffredi LA，Jacobs L，et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer [J]. Oncotarget，2015，6（6）：4527-4536.
[10] 陆洪俊，张倩.凯美纳治疗EGFR突变阳性肺癌脑转移15例临床观察[J].中华肿瘤防治杂志，2016，23（S1）：120-121.
[11] Fan Y，Huang Z，Fang L，et al. A phase Ⅱ study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer [J]. Cancer Chemother Pharmacol，2015，76（3）：517-523.
[12] 高庆壮，贺玉卿，张海杰，等.凯美纳联合全脑放疗治疗肺癌脑转移的近期疗效[J].今日健康，2016，15（9）：47.
[13] 曹丽玉，杜方民. 凯美纳联合全脑放疗治疗肺癌脑转移的近期疗效观察[J].世界最新医学信息文摘，2015， 15（90）：52-53.
[14] 滕菲，刘妙玲，崔桂敏，等.非小细胞肺癌脑转移患者头部放疗配合口服凯美纳疗效与不良反应观察[J].中国实用神经疾病杂志，2016，19（20）：75-76.
[15] He ZY，Li MF，Lin JH，et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases：a retrospective cohort study [J]. Cancer Manag Res，2019，11（1）：2129-2138.
[16] 董艳艳.盐酸埃克替尼治疗晚期非小细胞肺癌的效果观察[J].当代医药论丛，2019，17（14）：163-165.
[17] Magnuson WJ，Lester-Coll NH，Wu AJ，et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na?觙ve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis[J]. J Clin Oncol，2017，35（10）：1070-1077.
[18] 张小琴.盐酸埃克替尼治疗晚期非小细胞肺癌的疗效和安全性[J].中国基层医药，2017，24（23）：3621-3624.
[19] 陈本超，李恒，向旭东，等.埃克替尼联合放疗治疗肺癌脑转移疗效和安全性的Meta分析[J].临床荟萃，2018， 33（8）：705-710.
[20] 纪蓉，王建芳，孙彩萍，等.盐酸埃克替尼联合全脑放疗治疗非小细胞肺癌脑转移的随机对照研究[J].中国现代医生，2019，57（10）：29-33，37. |
|
|
|
